Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 2,804 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CFO William Richard White sold 2,804 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $53.99, for a total value of $151,387.96. Following the completion of the transaction, the chief financial officer now directly owns 59,155 shares in the company, valued at approximately $3,193,778.45. This represents a 4.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Akero Therapeutics Price Performance

Shares of NASDAQ:AKRO traded up $1.55 during trading on Friday, reaching $55.11. The stock had a trading volume of 1,356,860 shares, compared to its average volume of 1,476,598. The stock has a market capitalization of $4.39 billion, a PE ratio of -14.70 and a beta of -0.16. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 52 week low of $21.02 and a 52 week high of $58.40. The business's 50-day moving average price is $43.53 and its 200 day moving average price is $40.13.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. As a group, equities analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Citigroup decreased their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Bank of America lifted their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday, May 27th. Finally, HC Wainwright increased their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $82.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AKRO. Northwest & Ethical Investments L.P. bought a new position in shares of Akero Therapeutics in the first quarter worth about $32,000. GF Fund Management CO. LTD. bought a new position in Akero Therapeutics in the 4th quarter worth approximately $41,000. Sterling Capital Management LLC lifted its holdings in Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after buying an additional 1,582 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after buying an additional 390 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Akero Therapeutics in the 4th quarter valued at $83,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.